Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 2
1967 1
1968 2
1971 2
1976 2
1977 1
1979 1
1980 3
1981 3
1982 5
1983 4
1984 6
1985 3
1986 6
1987 6
1988 7
1989 16
1990 13
1991 18
1992 10
1993 20
1994 24
1995 14
1996 29
1997 23
1998 18
1999 24
2000 21
2001 29
2002 31
2003 47
2004 50
2005 73
2006 77
2007 94
2008 125
2009 141
2010 130
2011 158
2012 161
2013 208
2014 215
2015 309
2016 325
2017 352
2018 417
2019 506
2020 571
2021 629
2022 732
2023 10
Text availability
Article attribute
Article type
Publication date

Search Results

5,109 results
Results by year
Filters applied: . Clear all
Page 1
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.
Gallo D, Young JTF, Fourtounis J, Martino G, Álvarez-Quilón A, Bernier C, Duffy NM, Papp R, Roulston A, Stocco R, Szychowski J, Veloso A, Alam H, Baruah PS, Fortin AB, Bowlan J, Chaudhary N, Desjardins J, Dietrich E, Fournier S, Fugère-Desjardins C, Goullet de Rugy T, Leclaire ME, Liu B, Bhaskaran V, Mamane Y, Melo H, Nicolas O, Singhania A, Szilard RK, Tkáč J, Yin SY, Morris SJ, Zinda M, Marshall CG, Durocher D. Gallo D, et al. Among authors: yin sy. Nature. 2022 Apr;604(7907):749-756. doi: 10.1038/s41586-022-04638-9. Epub 2022 Apr 20. Nature. 2022. PMID: 35444283 Free PMC article.
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Cheah CY, Wei MC, Yin S, Li CC, Huang H, Kwan A, Penuel E, Bartlett NL. Budde LE, et al. Among authors: yin s. Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7. Epub 2022 Jul 5. Lancet Oncol. 2022. PMID: 35803286 Clinical Trial.
The role of aging in cancer.
Havas A, Yin S, Adams PD. Havas A, et al. Among authors: yin s. Mol Oncol. 2022 Sep;16(18):3213-3219. doi: 10.1002/1878-0261.13302. Mol Oncol. 2022. PMID: 36128609 Free PMC article.
Identification of three different phenotypes in anti-MDA5 antibody-positive dermatomyositis patients: implications for rapidly progressive interstitial lung disease prediction.
Xu L, You H, Wang L, Lv C, Yuan F, Li J, Wu M, Da Z, Wei H, Yan W, Zhou L, Yin S, Zhou D, Wu J, Lu Y, Su D, Liu Z, Liu L, Ma L, Xu X, Zang Y, Liu H, Ren T, Wang F, Du Y, Xue J, Zhang M, Tan W. Xu L, et al. Among authors: yin s. Arthritis Rheumatol. 2022 Jul 18. doi: 10.1002/art.42308. Online ahead of print. Arthritis Rheumatol. 2022. PMID: 35849805
Lipocalin-2 and Cerebral Stroke.
Luo C, Zhou S, Yin S, Jian L, Luo P, Dong J, Liu E. Luo C, et al. Among authors: yin s. Front Mol Neurosci. 2022 Apr 12;15:850849. doi: 10.3389/fnmol.2022.850849. eCollection 2022. Front Mol Neurosci. 2022. PMID: 35493318 Free PMC article. Review.
In vitro studies of maleidride-forming enzymes.
Yin S, Friedrich S, Hrupins V, Cox RJ. Yin S, et al. RSC Adv. 2021 Apr 21;11(25):14922-14931. doi: 10.1039/d1ra02118d. eCollection 2021 Apr 21. RSC Adv. 2021. PMID: 35424071 Free PMC article.
Ferroptosis and Its Role in Chronic Diseases.
Hu W, Liang K, Zhu H, Zhao C, Hu H, Yin S. Hu W, et al. Among authors: yin s. Cells. 2022 Jun 27;11(13):2040. doi: 10.3390/cells11132040. Cells. 2022. PMID: 35805124 Free PMC article. Review.
5,109 results